Stocklytics Platform
Asset logo for symbol AMED
Amedisys
AMED51
$97.54arrow_drop_up0.38%$0.37
Asset logo for symbol AMED
AMED51

$97.54

arrow_drop_up0.38%

Income Statement (AMED)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT$64.11M$52.28M$20.96M$59.40M$51.27M
EBITDA$70.47M$58.42M$25.10M$65.46M$65.81M
gross Profit$130.54M$117.66M$430.18M$244.60M$255.51M
NET Income$32.30M$14.40M$39.37M$25.96M-$80.27M
total Revenue$591.18M$571.41M$570.78M$556.23M$552.96M

Balance Sheet (AMED)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$317.28M$361.11M$341.35M$412.09M$391.40M
stockholders Equity$1.12B$1.08B$1.06B$1.03B$1.00B
total Assets$2.11B$2.08B$2.06B$2.02B$1.98B
total Debt$474.64M$481.81M$487.21M$490.20M$486.78M
total Liabilities$938.48M$947.21M$940.38M$933.89M$921.64M

Cash Flow (AMED)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow-$14.22M-$10.31M-$13.64M-$6.25M-$10.95M
free Cash Flow$50.73M-$9.43M$58.20M-$11.04M$52.90M
investing Cash Flow-----$7.74M
operating Cash Flow$52.30M-$6.54M$60.31M-$9.84M$60.75M

Amedisys (AMED) Financials

Amedisys Inc (AMED) is a leading provider of home health and hospice care services in the United States. The company's financial performance is reflected in its income statement, which shows its revenue, expenses, and net income. In the most recent financial period, Amedisys reported total revenue of $1.7 billion, representing a 6% increase compared to the previous year. The company's gross profit for the period was $682 million. Net income from stockholders was $67 million.
On the balance sheet, Amedisys has total assets of $2.3 billion, with total liabilities of $1.5 billion. The company's stockholders' equity is $755 million. The balance sheet also shows the company's cash equivalents, which stood at $132 million. Amedisys has a net debt of $29 million and total debt of $175 million. The company's cash flow statement provides insights into its operating, investing, and financing activities. Operating cash flow for the period was $147 million, while investing cash flow was -$103 million. Financing cash flow was $1 million, resulting in a free cash flow of $44 million.
add Amedisys  to watchlist

Keep an eye on Amedisys

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media